Developing novel therapeutics that modulate phosphoinositide (PI) signaling pathways for treatment of cancer


New York, NY


Series A


Acquired by global pharmaceutical company (2020)

Petra Pharma Corporation was launched to be a leader in phosphoinositide (PI) signaling pathway inhibition for the treatment of cancer and other serious diseases. PI signaling pathways play a central role in a variety of important cellular processes, including cell division, growth, trafficking, signaling, and impacting human health.

Petra Pharma was founded to advance the cutting-edge research from Weill Cornell Medicine and Dana-Farber Cancer Institute.

“I jumped at the opportunity to join Petra for three reasons: Company founder Lew Cantley’s incredible science; the Accelerator team’s commitment to supporting innovation – financially, operationally, and strategically; and the record-breaking $48 million Series A that Accelerator raised to advance the technology.”

— Brian O’Callaghan

Lewis C. Cantley, PhD
Nathanael S. Gray, PhD